JP2017530943A5 - - Google Patents

Download PDF

Info

Publication number
JP2017530943A5
JP2017530943A5 JP2017506931A JP2017506931A JP2017530943A5 JP 2017530943 A5 JP2017530943 A5 JP 2017530943A5 JP 2017506931 A JP2017506931 A JP 2017506931A JP 2017506931 A JP2017506931 A JP 2017506931A JP 2017530943 A5 JP2017530943 A5 JP 2017530943A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound
hydrocarbyl
hydride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017506931A
Other languages
English (en)
Japanese (ja)
Other versions
JP6353159B2 (ja
JP2017530943A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/043830 external-priority patent/WO2016022700A2/en
Publication of JP2017530943A publication Critical patent/JP2017530943A/ja
Publication of JP2017530943A5 publication Critical patent/JP2017530943A5/ja
Application granted granted Critical
Publication of JP6353159B2 publication Critical patent/JP6353159B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017506931A 2014-08-06 2015-08-05 Tlr非依存性低分子アジュバント Active JP6353159B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462033918P 2014-08-06 2014-08-06
US62/033,918 2014-08-06
PCT/US2015/043830 WO2016022700A2 (en) 2014-08-06 2015-08-05 Tlr-independent small molecule adjuvants

Publications (3)

Publication Number Publication Date
JP2017530943A JP2017530943A (ja) 2017-10-19
JP2017530943A5 true JP2017530943A5 (enExample) 2017-12-14
JP6353159B2 JP6353159B2 (ja) 2018-07-04

Family

ID=55264758

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017506931A Active JP6353159B2 (ja) 2014-08-06 2015-08-05 Tlr非依存性低分子アジュバント

Country Status (7)

Country Link
US (1) US9918959B2 (enExample)
EP (1) EP3177601B1 (enExample)
JP (1) JP6353159B2 (enExample)
AU (1) AU2015301100B2 (enExample)
CA (1) CA2957372C (enExample)
ES (1) ES2944541T3 (enExample)
WO (1) WO2016022700A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6964298B2 (ja) * 2016-06-29 2021-11-10 ザ スクリプス リサーチ インスティテュート ジプロボシム:新規かつ強力なクラスのtlrアゴニスト
EP3829571B1 (en) * 2018-08-02 2025-04-09 The Board Of Regents Of The University Of Texas System Adjuvant effect of the tlr1/2 agonist diprovocim synergizes with checkpoint-inhibiting antibodies to eliminate cancerous or infectious diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101304748A (zh) 2005-08-22 2008-11-12 加利福尼亚大学董事会 Tlr激动剂
HUE025555T2 (en) 2007-02-07 2016-02-29 Univ California Conjugates and applications of synthetic tlr agonists
WO2008112938A2 (en) * 2007-03-13 2008-09-18 New England Medical Center Hospitals, Inc. Composition and method for the treatment of diseases affected by a peptide receptor
PL2268618T3 (pl) * 2008-03-03 2015-11-30 Novartis Ag Związki i kompozycje jako modulatory aktywności receptorów TLR

Similar Documents

Publication Publication Date Title
JP2016515561A5 (enExample)
JP2020534355A5 (enExample)
JP2011518833A5 (enExample)
JP2013032389A5 (enExample)
JP2016503793A5 (enExample)
JP2015078230A5 (enExample)
JP2011105738A5 (enExample)
JP2021502388A5 (enExample)
JP2017506666A5 (enExample)
JP2017533930A5 (enExample)
JP2018521056A5 (enExample)
JP2018531941A5 (enExample)
JP2017514910A5 (enExample)
JP2015512946A5 (enExample)
JP2012532883A5 (enExample)
JP2011527299A5 (enExample)
JP2020500916A5 (enExample)
JP2016505614A5 (enExample)
JP2020097577A5 (enExample)
JP2019535723A5 (enExample)
JP2015007131A5 (enExample)
JP2015516427A5 (enExample)
JP2018538273A5 (enExample)
CN110139863A (zh) 作为雌激素受体降解剂的吲哚并取代哌啶类化合物
JP2017517565A5 (enExample)